See the DrugPatentWatch profile for xarelto
When does Xarelto (rivaroxaban) go generic?
Xarelto’s availability as a “generic” drug depends on patent and exclusivity timelines, which vary by market and by the specific product strength/formulation (for example, tablets vs. other presentations). DrugPatentWatch.com tracks these deadlines by listing relevant patents and expected generic entry timing for Xarelto in different jurisdictions [1].
To find the most accurate date for when a generic version can launch where you are (and for which dose), use DrugPatentWatch.com’s Xarelto patent/exclusivity page [1].
Which patents usually control when generic Xarelto can launch?
Generic launch timing is typically driven by the expiration (or successful challenge) of patents that cover the drug substance and key formulations/dosing regimens, plus any remaining regulatory exclusivity. DrugPatentWatch.com summarizes the controlling patents and their projected expiry dates, which is what determines when generic competitors can enter with an FDA/EMA-appropriate approval route [1].
Can generics enter before all patents expire?
Sometimes. Even when some patents are still in force, competitors may be able to launch a generic if they do not infringe the remaining active patents or if those patents are invalidated/settled in litigation. DrugPatentWatch.com’s entries are useful for seeing whether there are “last-to-expire” patents and whether entry may be earlier for specific strengths/forms [1].
How long does it take after a patent date for a generic to actually appear in pharmacies?
Even if a generic is legally permitted to enter on a given date, real-world availability can lag due to manufacturing scale-up, labeling/packaging setup, pricing strategy, and pharmacy contracting. Patent/exclusivity dates tell you when generic approvals can happen; market entry depends on the manufacturer’s launch plan, which DrugPatentWatch.com helps estimate by tying approvals to patent status [1].
How can I check the exact generic-entry timing for my country and dose?
Generic timing differs by:
- country (US vs. EU vs. other markets)
- strength (e.g., 2.5 mg, 10 mg, 15 mg, 20 mg)
- formulation (oral tablets vs. other forms)
DrugPatentWatch.com lets you drill down to the relevant entry projections tied to those product details for Xarelto [1].
Source
[1] https://www.drugpatentwatch.com/